ISM3412
Insilico Medicine: company profile
Phase 1/2 registry
Since , the date of the source that reports this phase.
Summary
ISM3412 is a program from Insilico Medicine. The source describes it as small molecule. It is being developed for locally advanced or metastatic solid tumors (MTAP-deleted). ClinicalTrials.gov lists it at Phase 1/2 (recruiting) under NCT06414460. The AI role named in the source is molecule design. Registry records: NCT06414460, Phase 1/2, recruiting, updated Sep 1, 2026. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. First patient dosed per post. The latest dated source is from Jun 27, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine
- Indication
- Locally advanced or metastatic solid tumors (MTAP-deleted)
- Therapeutic area
- Oncology
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Phase 1/2, as of Jun 27, 2025
- Phase source
- Registry
- Board column
- Phase 1
Key readouts in the source
First patient dosed per post
AI evidence
AI source: Company
“ISM3412, a potentially best-in-class, AI-empowered MAT2A inhibitor with a novel structure”
Trial records
- NCT06414460 on ClinicalTrials.gov (opens in new tab) Phase 1/2 Recruiting Updated
Milestone timeline
-
ClinicalTrials.gov record: Phase 1/2
First patient dosed per post
-
NCT06414460 record updated
Phase 1/2, Recruiting
-
Registry check
Registry Phase 1/2 vs post Phase 1.
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.